Full text is available at the source.
Abstract
In a meta-analysis of three randomized controlled trials involving 2,505 participants, orforglipron demonstrated reductions in body weight of up to 7.80% compared to placebo.
- Weight reductions ranged from 2.43% at a 3 mg dose to 7.80% at a 24 mg dose.
- Body mass index (BMI) reductions varied from 0.88 kg/m² at 3 mg to 2.70 kg/m² at 45 mg.
- Significant waist circumference reductions were noted at doses of 6 mg or higher, reaching 5.90 cm at 24 mg.
- Glycated hemoglobin (HbA1c) levels decreased by 0.80% at 3 mg and 1.67% at 45 mg.
- Fasting serum glucose levels declined from 20.62 mg/dL at 3 mg to 44.80 mg/dL at 45 mg.
- Increased treatment discontinuation due to adverse events was observed with orforglipron, but serious adverse events were not significantly different from placebo.
Simplified